Takara Bio USA, Inc. today announced a benchmark study comparing the performance of its Trekker® FX technology against ...

Validation study targets sub-3-minute results to capture global roadside testing market and significantly reduce analysis time from 10 minutes U.S. Roadside drug testing market projected to reach ...

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

The last time I spoke about Tourmaline Bio (TRML) it was with respect to a Seeking Alpha article entitled "Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting." In this article, I ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies ...

The MarketWatch News Department was not involved in the creation of this content. MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. ("Klothea Bio"), a clinical-stage biotechnology company ...

Climb Bio, Inc. stays a Buy on budoprutug pMN data; Phase 2 PrisMN readout 2H 2026 + SLE/ITP upside and 2028 cash runway.

The study's main contributors include (L-R) graduate student Joshua Shaffer, professor Upasna Sharma, and postdoc Alka Gupta. (Photo by Carolyn Lagattuta) The pioneering research of UC Santa Cruz’s ...

Autism and Alzheimer’s disease have long occupied separate corners of neuroscience. One is diagnosed in childhood; the other ...

SAB BIO has announced a $175 million private placement financing to fund its pivotal Phase 2b SAFEGUARD study of SAB-142, aimed at delaying the progression of autoimmune type 1 diabetes (T1D) in newly ...

GRI Bio, Inc. has received a recommendation from the Independent Data Monitoring Committee to continue its Phase 2a study of GRI-0621 for the treatment of idiopathic pulmonary fibrosis (IPF) following ...